HomeREGULATORY
REGULATORY

Pricing OK’ed for Hemlibra, Parmodia; Prevymis 1st in 3 Years to Get At-Launch Premium for Innovation
(May.17.2018)

The health ministry’s key reimbursement panel approved on May 16 the NHI price listing of a slew of new medicines, including MSD’s cytomegalovirus (CMV) chemotherapy Prevymis (letermovir). Listing is scheduled for May 22 ...
(LOG IN FOR FULL STORY)